BioVex held a $22 million first close on a Series E that will enable the company to move a treatment for advanced melanoma into pivotal U.S. trials. New investor Triathlon Medical Ventures is leading the round and so far has been joined by one other new backer, New Science Ventures. Return investors include ABN Amro, Avalon Ventures, Credit Agricole Private Equity, GeneChem Management, Innoven Partners and Scottish Equity Partners.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.